IRWD · Ironwood Pharmaceuticals Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 159.71M | Six Months Ended June 30, 2026 | — |
| Collaboration revenue to Ironwood from LINZESS U.S. | $110M | Q2 2026 | — |
|
|
|||
| Commercial margin | 77% | Six Months Ended June 30, 2026 | — |
| Ironwood's U.S. collaborative arrangements revenue | 214.27M | Six Months Ended June 30, 2026 | — |
| LINZESS commercial margin | 78% | Q2 2026 | — |
|
|
|||
| LINZESS U.S. net sales as reported by AbbVie | 554.83M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Non-GAAP net income non-GAAP | 92.44M | Six Months Ended June 30, 2026 | — |
| Non-GAAP net income (loss) per share – basic non-GAAP | $0.56 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Non-GAAP net income (loss) per share – diluted non-GAAP | $0.55 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Total LINZESS demand | 59.8M | Q2 2026 | — |
| Total net profit on sales of LINZESS | 419.34M | Six Months Ended June 30, 2026 | — |
|
|
|||
| LINZESS EUTRx demand growth | 5% | Q1 2026 | — |
| Non-GAAP net income (loss) non-GAAP | 40.95M | Q1 2026 | — |
| Total LINZESS prescription demand | 234M | FY 2025 | — |
| Unique patients treated with LINZESS since launch | 5.7M | FY 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IRWD
this stock
Ironwood Pharmaceuticals Inc
|
$720.45M | +22.8% | +8.9% | 5.7 | 10.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.85B | +16.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.82B | +1.7% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.94B | -2.4% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IRWD | +1.5% | +9.2% | +21.1% | -2.1% | +22.9% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +3.4% | +5.9% | +9.9% | -4.2% | +11.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.